share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  07/01 06:24
Moomoo AI 已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has announced the issuance of unquoted equity securities under an employee incentive scheme. The announcement, dated June 28, 2024, detailed the issue of three new classes of options not intended to be quoted on the ASX. These options, with expiry dates ranging from March 13 to March 21, 2029, and exercise prices between AUD 0.004 and USD 0.003, were issued on June 27, 2024. A total of 209 million options were distributed across the three classes, with the largest single issuance of 120 million options granted to David Stamler, a key management personnel. The options, upon exercise, will convert into ordinary fully paid shares of Alterity Therapeutics. The company confirmed that the securities were issued under an exception in Listing Rule 7.2, negating the need for security holder approval.
Alterity Therapeutics Limited, a development stage enterprise, has announced the issuance of unquoted equity securities under an employee incentive scheme. The announcement, dated June 28, 2024, detailed the issue of three new classes of options not intended to be quoted on the ASX. These options, with expiry dates ranging from March 13 to March 21, 2029, and exercise prices between AUD 0.004 and USD 0.003, were issued on June 27, 2024. A total of 209 million options were distributed across the three classes, with the largest single issuance of 120 million options granted to David Stamler, a key management personnel. The options, upon exercise, will convert into ordinary fully paid shares of Alterity Therapeutics. The company confirmed that the securities were issued under an exception in Listing Rule 7.2, negating the need for security holder approval.
Alterity Therapeutics有限公司，一家發展階段企業，宣佈在員工激勵計劃下發行非上市股權證券。該公告日期爲2024年6月28日，詳細介紹了發行三種新型期權，不打算在ASX上掛牌交易。這些期權的到期日從2029年3月13日至3月21日不等，行使價格介於AUD 0.004和美元指數0.003之間，在2024年6月27日發行。共發行了3類2.09億期權，其中最大的單次發行量爲1.2億期權，授予關鍵管理人員David Stamler。行使期權後，這些證券將轉換爲Alterity Therapeutics普通已全額支付的股份。該公司確認，所發行證券符合《7.2號上市規則》中的例外情況，不需要證券持有人的批准。
Alterity Therapeutics有限公司，一家發展階段企業，宣佈在員工激勵計劃下發行非上市股權證券。該公告日期爲2024年6月28日，詳細介紹了發行三種新型期權，不打算在ASX上掛牌交易。這些期權的到期日從2029年3月13日至3月21日不等，行使價格介於AUD 0.004和美元指數0.003之間，在2024年6月27日發行。共發行了3類2.09億期權，其中最大的單次發行量爲1.2億期權，授予關鍵管理人員David Stamler。行使期權後，這些證券將轉換爲Alterity Therapeutics普通已全額支付的股份。該公司確認，所發行證券符合《7.2號上市規則》中的例外情況，不需要證券持有人的批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息